Could Buying This Weight Loss Stock Be Like Investing in Novo Nordisk At The Dawn of The GLP-1 Revolution?

The healthcare industry is abuzz with GLP-1 agonists like Ozempic and Wegovy for treating diabetes and obesity. Viking Therapeutics is a key player with potential in the weight loss market, particularly with its dual GLP-1 and GIP receptor agonist VK2735.